Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines

Abstract

Imidazo-quinoline, -pyridine, and -naphthyridine ring systems (particularly quinolines, tetrahydroquinolines, pyridines, [1,5]naphthyridines, [1,5]tetrahydronaphthyridines) substituted at the 1-position with a cyclic substituent, pharmaceutical compositions containing the compounds, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

What is claimed is: 
     
         1 . A compound of the Formula (I): 
       
         
           
           
               
               
           
         
         wherein:
 m is an integer from 1 to 5; 
 R′ is selected from the group consisting of:
 hydroxy, 
 thiol, 
 —S(O) 0-2 -alkyl, 
 —S(O) 2 —NH—R 9 , 
 alkoxy, 
 —O—C 1-3  alkylene-S(O) 2 -alkyl, 
 —N(R 9 ) 2 , and 
 —NH-Q-R 4 ; 
 
 Z is selected from the group consisting of:
 a bond, 
 C 1-5  alkylene, 
 
 
       
       
         
           
           
               
               
           
         
         
           A′ is selected from the group consisting of:
 —O—, 
 —C(O)—, 
 —N(R 8 )—, 
 —N(Q-R 4 )—, 
 —N(C 1-5  alkylene-NH-Q-R 4 )—, 
 —N(C 1-5  alkylene-W—NH—R 8 )—, and 
 —S(O) 0-2 —; 
 
         
         R 2  is selected from the group consisting of:
 —R 4 , 
 —X—R 4 , 
 —X—Y—R 4 , and 
 —X—R 5 ; 
 
         when taken together, R A  and R B  form a fused heteroaryl ring containing one heteroatom selected from the group consisting of N and S wherein the heteroaryl ring is unsubstituted or substituted by one or more R groups; 
         or when taken together, R A  and R B  form a fused 5 to 7 membered saturated ring, containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups;
 R is selected from the group consisting of:
 halogen, 
 hydroxy, 
 alkyl, 
 alkenyl, 
 haloalkyl, 
 alkoxy, 
 alkylthio, and 
 —N(R 9 ) 2 ; 
 
 X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by one or more —O— groups; 
 Y is selected from the group consisting of:
 —S(O) 0-2 —, 
 —S(O) 2 —N(R 8 )—, 
 —C(R 6 )—, 
 —C(R 6 )—O—, 
 —O—C(R 6 )—, 
 —O—C(O)—O—, 
 —N(R 8 )-Q-, 
 —C(R 6 )—N(R 8 )—, 
 —O—C(R 6 )—N(R 8 )—, 
 —C(R 6 )—N(OR 9 )—, 
 
 
       
       
         
           
           
               
               
           
         
         
           R 4  is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, acetylamino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo; 
           R 5  is selected from the group consisting of: 
         
       
       
         
           
           
               
               
           
         
         
           R 6  is selected from the group consisting of ═O and ═S; 
           R 7  is C 2-7  alkylene; 
           R 8  is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl; 
           R 9  is selected from the group consisting of hydrogen and alkyl; 
           R 10  is C 3-8  alkylene; 
           R 11  is selected from the group consisting of hydrogen, alkyl, halogen, and trifluoromethyl; 
           R 12  is selected from the group consisting of hydrogen, alkyl, phenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl; 
           A is selected from the group consisting of —O—, —C(O)—, —S(O) 0-2 —, —CH 2 —, and —N(R 4 )—; 
           Q is selected from the group consisting of a bond, —C(R 6 )—, —C(R 6 )—C(R 6 ), —S(O) 2 —, —C(R 6 )—N(R 8 )—W—, —S(O) 2 —N(R 8 )—, —C(R 6 )—O—, and —C(R 6 )—N(OR 9 )—; and 
           V is selected from the group consisting of —C(R 6 )—, —O—C(R 6 )—, —N(R 8 )—C(R 6 )—, and —S(O) 2 —; 
           W is selected from the group consisting of a bond, —C(O)—, and —S(O) 2 —; and 
           a and b are independently integers from 1 to 6 with the proviso that a+b is ≤7; 
           with the proviso that when Z is a bond or C 1-5  alkylene then R′ is other than —O—C 1-3  alkylene-S(O) 2 -alkyl, and with the further proviso that when Z is a bond or C 1-5  and R 2  is —X—Y—R 4  and Y is —N(R 8 )-Q-, then Q is other than —C(R 6 )—N(R 8 )—W—; 
           or a pharmaceutically acceptable salt thereof. 
         
       
     
     
         2 . A compound of the Formula (V): 
       
         
           
           
               
               
           
         
         wherein:
 m is an integer from 1 to 5; 
 p is an integer from 0 to 3; 
 R′ is selected from the group consisting of:
 hydroxy, 
 thiol, 
 —S(O) 0-2 -alkyl, 
 —S(O) 2 —NH—R 9 , 
 alkoxy, 
 —O—C 1-3  alkylene-S(O) 2 -alkyl, 
 —N(R 9 ) 2 , and 
 —NH-Q-R 4 ; 
 
 Z is selected from the group consisting of:
 a bond, 
 C 1-5  alkylene, 
 
 
       
       
         
           
           
               
               
           
         
         
           A′ is selected from the group consisting of:
 —O—, 
 —C(O)—, 
 —N(R 8 )—, 
 —N(Q-R 4 )—, 
 —N(C 1-5  alkylene-NH-Q-R 4 )—, 
 —N(C 1-5  alkylene-W—NH—R 8 )—, and 
 —S(O) 0-2 —; 
 
           R 2  is selected from the group consisting of:
 —R 4 , 
 —X—R 4 , 
 —X—Y—R 4 , and 
 —X—R 5 ; 
 
           R is selected from the group consisting of:
 halogen, 
 hydroxy, 
 alkyl, 
 alkenyl, 
 haloalkyl, 
 alkoxy, 
 alkylthio, and 
 —N(R 9 ) 2 ; 
 
           X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by one or more —O— groups; 
           Y is selected from the group consisting of:
 —S(O) 0-2 —, 
 —S(O) 2 —N(R 8 )—, 
 —C(R 6 )—, 
 —C(R 6 )—O—, 
 —O—C(R 6 )—, 
 —O—C(O)—O—, 
 —N(R 8 )-Q-, 
 —C(R 6 )—N(R 8 )—, 
 —O—C(R 6 )—N(R 8 )—, 
 —C(R 6 )—N(OR 9 )—, 
 
         
       
       
         
           
           
               
               
           
         
         
           R 4  is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, acetylamino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo; 
           R 5  is selected from the group consisting of: 
         
       
       
         
           
           
               
               
           
         
         
           R 6  is selected from the group consisting of ═O and ═S; 
           R 7  is C 2-7  alkylene; 
           R 8  is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl; 
           R 9  is selected from the group consisting of hydrogen and alkyl; 
           R 10  is C 3-8  alkylene; 
           R 11  is selected from the group consisting of hydrogen, alkyl, halogen, and trifluoromethyl; 
           R 12  is selected from the group consisting of hydrogen, alkyl, phenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl; 
           A is selected from the group consisting of —O—, —C(O)—, —S(O) 0-2 —, —CH 2 —, and —N(R 4 )—; 
           Q is selected from the group consisting of a bond, —C(R 6 )—, —C(R 6 )—C(R 6 ), —S(O) 2 —, —C(R 6 )—N(R 8 )—W—, —S(O) 2 —N(R 8 )—, —C(R 6 )—O—, and —C(R 6 )—N(OR 9 )—; 
           V is selected from the group consisting of —C(R 6 )—, —O—C(R 6 )—, —N(R 8 )—C(R 6 )—, and —S(O) 2 —; 
           W is selected from the group consisting of a bond, —C(O)—, and —S(O) 2 —; and 
           a and b are independently integers from 1 to 6 with the proviso that a+b is ≤7; 
           with the proviso that when Z is a bond or C 1-5  alkylene then R′ is other than —O—C 1-3  alkylene-S(O) 2 -alkyl, and with the further proviso that when Z is a bond or C 1-5  alkylene and R 2  is —X—Y—R 4  and Y is —N(R 8 )-Q-, then Q is other than —C(R 6 )—N(R 8 )—W—; 
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         3 . The compound or salt of  claim 2  wherein p is 0. 
     
     
         4 . The compound or salt of  claim 2  wherein m is 1. 
     
     
         5 . The compound or salt of  claim 2  wherein Z is selected from the group consisting of a bond and C 1-3  alkylene. 
     
     
         6 . The compound or salt of  claim 2  wherein Z is —(CH 2 ) 0-1 -A′-(CH 2 ) 0-1 —. 
     
     
         7 . The compound or salt of  claim 6  wherein A′ is —O—. 
     
     
         8 . The compound or salt of  claim 6  wherein A′ is —N(R 8 )— or —N(Q-R 4 )—. 
     
     
         9 . The compound or salt of  claim 8  wherein Q is —S(O) 2 — and R 4  is C 1-4  alkyl. 
     
     
         10 . The compound or salt of  claim 2  wherein the compound is of the following formula: 
       
         
           
           
               
               
           
         
         wherein:
 Z is a bond or C 1-3  alkylene; and 
 R 2  is selected from the group consisting of hydrogen, C 1-4  alkyl, HO—C 1-4  alkylenyl, and C 1-4  alkyl-O—C 1-4  alkylenyl; 
 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         11 . The compound or salt of  claim 2  wherein the compound is of the following Formula: 
       
         
           
           
               
               
           
         
         wherein R 2  is selected from the group consisting of hydrogen, C 1-4  alkyl, HO—C 1-4  alkylenyl, and C 1-4  alkyl-O—C 1-4  alkylenyl; or a pharmaceutically acceptable salt thereof. 
       
     
     
         12 . The compound or salt of  claim 2  wherein R′ is hydroxy. 
     
     
         13 . The compound or salt of  claim 2  wherein R 2  is hydrogen, C 1-4  alkyl, HO—C 1-4  alkylenyl, or C 1-4  alkyl-O—C 1-4  alkylenyl. 
     
     
         14 . The compound or salt of  claim 2 , wherein R′ is selected from the group consisting of —NH 2  and —NH-Q-R 4 , wherein:
 Q is selected from the group consisting of —C(O)—, —C(O)—O—, —S(O) 2 —, and —C(R 6 )—N(R 8 )—, wherein R 8  is selected from hydrogen and C 1-4  alkyl; and 
 R 4  is alkyl, aryl, arylalkylene, heteroaryl, and heterocyclyl, wherein the aryl group can be unsubstituted or substituted by acetylamino, alkyl, alkoxy, cyano, and halogen. 
 
     
     
         15 . The compound or salt of  claim 2  wherein:
 R 2  is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, hydroxyalkylenyl, and —X—Y—R 4 , wherein:
 X is C 1-2  alkylene; 
 Y is selected from the group consisting of —S(O) 0-2 —, —S(O) 2 —N(R 8 )—, —C(R 6 )—, —C(R 6 )—O—, —O—C(R 6 )—, —O—C(O)—O—, —N(R 8 )-Q-, —C(R 6 )—N(R 8 )—, —O—C(R 6 )—N(R 8 )—, and —C(R 6 )—N(OR 9 )—; and 
 R 4  is alkyl. 
 
 
     
     
         16 . A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of  claim 1  in combination with a pharmaceutically acceptable carrier. 
     
     
         17 . A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of  claim 1  to the animal. 
     
     
         18 . A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of  claim 1  to the animal. 
     
     
         19 . A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of  claim 1  to the animal. 
     
     
         20 . A compound of the Formula (X): 
       
         
           
           
               
               
           
         
         wherein:
 m is an integer from 1 to 5; 
 R′ is selected from the group consisting of:
 hydroxy, 
 thiol, 
 —S(O) 0-2 -alkyl, 
 —S(O) 2 —NH—R 9 , 
 alkoxy, 
 —O—C 1-3  alkylene-S(O) 2 -alkyl, 
 —N(R 9 ) 2 , and 
 —NH-Q-R 4 ; 
 
 Z is selected from the group consisting of:
 a bond, 
 C 1-5  alkylene, 
 
 
       
       
         
           
           
               
               
           
         
         
           A′ is selected from the group consisting of:
 —O—, 
 —C(O)—, 
 —N(R 8 )—, 
 —N(Q-R 4 )—, 
 —N(C 1-5  alkylene-NH-Q-R 4 )—, 
 —N(C 1-5  alkylene-W—NH—R 8 )—, and 
 —S(O) 0-2 —; 
 
           R 2  is selected from the group consisting of:
 —R 4 , 
 —X—R 4 , 
 —X—Y—R 4 , and 
 —X—R 5 ; 
 
           when taken together, R A  and R B  form a fused heteroaryl ring containing one heteroatom selected from the group consisting of N and S wherein the heteroaryl ring is unsubstituted or substituted by one or more R groups; 
           or when taken together, R A  and R B  form a fused 5 to 7 membered saturated ring, containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups; 
           R is selected from the group consisting of:
 halogen, 
 hydroxy, 
 alkyl, 
 alkenyl, 
 haloalkyl, 
 alkoxy, 
 alkylthio, and 
 —N(R 9 ) 2 ; 
 
           X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by one or more —O— groups; 
           Y is selected from the group consisting of:
 —S(O) 0-2 —, 
 —S(O) 2 —N(R 8 )—, 
 —C(R 6 )—, 
 —C(R 6 )—O—, 
 —O—C(R 6 )—, 
 —O—C(O)—O—, 
 —N(R 8 )-Q-, 
 —C(R 6 )—N(R 8 )—, 
 —O—C(R 6 )—N(R 8 )—, 
 —C(R 6 )—N(OR 9 )—, 
 
         
       
       
         
           
           
               
               
           
         
         
           R 4  is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, acetylamino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo; 
           R 5  is selected from the group consisting of: 
         
       
       
         
           
           
               
               
           
         
         
           R 6  is selected from the group consisting of ═O and ═S; 
           R 7  is C 2-7  alkylene; 
           R 8  is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl; 
           R 9  is selected from the group consisting of hydrogen and alkyl; 
           R 10  is C 3-8  alkylene; 
           R 11  is selected from the group consisting of hydrogen, alkyl, halogen, and trifluoromethyl; 
           R 12  is selected from the group consisting of hydrogen, alkyl, phenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl; 
           A is selected from the group consisting of —O—, —C(O)—, —S(O) 0-2 —, —CH 2 —, and —N(R 4 )—; 
           Q is selected from the group consisting of a bond, —C(R 6 )—, —C(R 6 )—C(R 6 ), —S(O) 2 —, —C(R 6 )—N(R 8 )—W—, —S(O) 2 —N(R 8 )—, —C(R 6 )—O—, and —C(R 6 )—N(OR 9 )—; 
           V is selected from the group consisting of —C(R 6 )—, —O—C(R 6 )—, —N(R 8 )—C(R 6 )—, and —S(O) 2 —; 
           W is selected from the group consisting of a bond, —C(O)—, and —S(O) 2 —; and 
           a and b are independently integers from 1 to 6 with the proviso that a+b is ≤7; 
           G is selected from the group consisting of:
 —C(O)—R″, 
 α-aminoacyl, 
 α-aminoacyl-α-aminoacyl, 
 —C(O)—O—R″, 
 —C(O)—N(R″′)R″, 
 —C(═NY′)—R″, 
 —CH(OH)—C(O)—OY′, 
 —CH(OC 1-4  alkyl)Y 0 , 
 —CH 2 Y 1 , and 
 —CH(CH 3 )Y 1 ; 
 
         
         R″ and R″′ are independently selected from the group consisting of C 1-10  alkyl, C 3-7  cycloalkyl, and benzyl, each of which may be unsubstituted or substituted by one or more substitutents selected from the group consisting of halogen, hydroxy, nitro, cyano, carboxy, C 1-6  alkyl, C 1-4  alkoxy, aryl, heteroaryl, arylC 1-4  alkylenyl, heteroarylC 1-4  alkylenyl, haloC 1-4  alkylenyl, haloC 1-4  alkoxy, —O—C(O)—CH 3 , —C(O)—O—CH 3 , —C(O)—NH 2 , —O—CH 2 —C(O)—NH 2 , —NH 2 , and —S(O) 2 —NH 2 , with the proviso that R″′ can also be hydrogen;
 α-aminoacyl is an acyl group derived from an amino acid selected from the group consisting of racemic, D-, and L-amino acids; 
 Y′ is selected from the group consisting of hydrogen, C 1-6  alkyl, and benzyl; 
 Y 0  is selected from the group consisting of C 1-6  alkyl, carboxyC 1-6  alkylenyl, aminoC 1-4  alkylenyl, mono-N—C 1-6  alkylaminoC 1-4  alkylenyl, and di-N,N—C 1-6  alkylaminoC 1-4  alkylenyl; and 
 Y 1  is selected from the group consisting of mono-N—C 1-6  alkylamino, di-N,N—C 1-6  alkylamino, morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, and 4-C 1-4  alkylpiperazin-1-yl; 
 with the proviso that when Z is a bond or C 1-5  alkylene then R′ is other than —O—C 1-3  alkylene-S(O) 2 -alkyl, and with the further proviso that when Z is a bond or C 1-5  alkylene and R 2  is —X—Y—R 4  and Y is —N(R 8 )-Q-, then Q is other than —C(R 6 )—N(R 8 )—W—; 
 
         or a pharmaceutically acceptable salt thereof.